Security Snapshot

SAREPTA THERAPEUTICS INC - NOTE 1.250% 9/1 Institutional Ownership

CUSIP: 803607AD2

13F Institutional Holders and Ownership History from Q3 2023 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

21

Principal

$147,551,900

Price (% of par)

92.05%

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 3 signals
Principal change
+$40,000
Market value change
+$164,445
Number of holders
21
Issuer context Names, identifiers, and filing context for this profile. 1 identity field
SEC-reported market price (% of par)
92.05%
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • 803607AD2 - SAREPTA THERAPEUTICS INC - NOTE 1.250% 9/1 is tracked under CUSIP 803607AD2.
  • 21 institutions reported positions in Q1 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 18 to 21 between Q4 2025 and Q1 2026.
  • SEC-reported value moved from $133,215,981 to $138,224,793.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 21 institutions filings for Q1 2026.

Open SEC evidence

Security key

803607AD2

Latest holder period

Q1 2026

13F holders

21

13D/G owners

0

CIK / CUSIP context first

As of 31 Mar 2026, 21 institutional investors reported holding $147,551,900 in principal (par value) of SAREPTA THERAPEUTICS INC - NOTE 1.250% 9/1.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
11
Latest
Q1 2026
Rows shown
1-11 of 11
Period Principal Value Change Price (% of par) (Median) Investors
2026 Q1 $147,551,900 $138,224,793 +$164,445 92.05% 21
2025 Q4 $147,511,900 $133,215,981 -$243,157,718 89.64% 18
2025 Q3 $423,204,030 $373,473,256 -$483,579,093 87.97% 30
2025 Q2 $1,009,456,484 $771,135,004 -$30,695,954 73.38% 57
2025 Q1 $987,578,288 $920,780,195 +$32,593,408 93.16% 75
2024 Q4 $919,250,180 $1,045,725,240 -$29,748,516 110.1% 77
2024 Q3 $935,735,828 $1,097,325,738 -$3,339,388 113.6% 72
2024 Q2 $955,302,856 $1,269,526,221 -$95,435,668 128.9% 75
2024 Q1 $1,029,532,211 $1,208,334,847 +$7,418,505 116.91% 63
2023 Q4 $1,039,757,323 $1,059,310,870 +$23,391,526 101.51% 64
2023 Q3 $1,003,179,309 $1,128,882,513 +$1,128,882,326 112.15% 64
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .